CA2656620C - Cd20 binding molecules for the treatment of copd - Google Patents

Cd20 binding molecules for the treatment of copd Download PDF

Info

Publication number
CA2656620C
CA2656620C CA2656620A CA2656620A CA2656620C CA 2656620 C CA2656620 C CA 2656620C CA 2656620 A CA2656620 A CA 2656620A CA 2656620 A CA2656620 A CA 2656620A CA 2656620 C CA2656620 C CA 2656620C
Authority
CA
Canada
Prior art keywords
antibody
human
mutant
use according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2656620A
Other languages
English (en)
French (fr)
Other versions
CA2656620A1 (en
Inventor
Paul Parren
Steen Lisby
Ole Baadsgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of CA2656620A1 publication Critical patent/CA2656620A1/en
Application granted granted Critical
Publication of CA2656620C publication Critical patent/CA2656620C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2656620A 2006-07-04 2007-07-04 Cd20 binding molecules for the treatment of copd Active CA2656620C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200600916 2006-07-04
DKPA200600916 2006-07-04
US81859306P 2006-07-05 2006-07-05
US60/818,593 2006-07-05
PCT/DK2007/000339 WO2008003319A1 (en) 2006-07-04 2007-07-04 Cd20 binding molecules for the treatment of copd

Publications (2)

Publication Number Publication Date
CA2656620A1 CA2656620A1 (en) 2008-01-10
CA2656620C true CA2656620C (en) 2018-03-13

Family

ID=47390906

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2656620A Active CA2656620C (en) 2006-07-04 2007-07-04 Cd20 binding molecules for the treatment of copd

Country Status (5)

Country Link
US (1) US20130004480A1 (enExample)
EP (1) EP2046383B1 (enExample)
JP (2) JP5605895B2 (enExample)
CA (1) CA2656620C (enExample)
WO (1) WO2008003319A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
RU2386438C1 (ru) * 2008-12-04 2010-04-20 Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава Способ комплексного лечения хронической обструктивной болезни легких в стадии ремиссии
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
EP3578568A3 (en) 2010-11-08 2020-01-08 Ablynx N.V. Cxcr2 binding polypeptides
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2016168565A1 (en) * 2015-04-16 2016-10-20 President And Fellows Of Harvard College Methods for treatment of chronic obstructive pulmonary disease and/or therapy monitoring
US20180096104A1 (en) * 2016-10-05 2018-04-05 MED Inc. Disease management system
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
JP7482866B2 (ja) 2018-11-19 2024-05-14 ビオラ・セラピューティクス・インコーポレイテッド 生物学的治療薬による疾患処置方法およびデバイス
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
EP4626447A1 (en) 2023-03-31 2025-10-08 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
CA2422155A1 (en) 2000-08-03 2002-02-14 Wim Van Schooten Production of humanized antibodies in transgenic animals
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
RU2335507C2 (ru) 2001-06-13 2008-10-10 Генмаб А/С Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7507753B2 (en) * 2001-12-28 2009-03-24 Takeda Chemical Industries Ltd. Biaryl compound and use thereof
AU2003208415B2 (en) 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
EA021644B1 (ru) 2002-10-17 2015-08-31 Генмаб А/С Человеческое моноклональное антитело против cd20 и его применение
BRPI0316282B8 (pt) 2002-11-15 2021-05-25 Genmab As anticorpo humano isolado monoclonal, composição, imunoconjugado, molécula biespecífica ou multiespecífica, método e conjunto de diagnóstico para detectar a presença de antígeno cd25 ou uma célula que expressa cd25, e, vetor de expressão
EP1590364B1 (en) 2002-12-16 2011-10-05 Genmab A/S Human monoclonal antibodies against interleukin 8 (il-8)
PL212899B1 (pl) 2002-12-16 2012-12-31 Genentech Inc Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
GB0324888D0 (en) * 2003-10-24 2003-11-26 Novartis Ag Organic compounds
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
BRPI0512915A (pt) * 2004-06-29 2008-04-15 Warner Lambert Co terapias de combinação utilizando inibidores benzamida do receptor p2x7
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー／エス 組換え一価抗体およびその作製方法

Also Published As

Publication number Publication date
WO2008003319A1 (en) 2008-01-10
JP5605895B2 (ja) 2014-10-15
CA2656620A1 (en) 2008-01-10
JP2009541374A (ja) 2009-11-26
JP2014208651A (ja) 2014-11-06
EP2046383A1 (en) 2009-04-15
EP2046383B1 (en) 2014-11-19
US20130004480A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
CA2656620C (en) Cd20 binding molecules for the treatment of copd
US7943342B2 (en) Nucleic acids encoding IL-13 binding agents
EP3277722B1 (en) Antibodies to canine interleukin-4 receptor alpha
RU2755691C2 (ru) Il-18-связывающие белок (il-18bp) и антитела при воспалительных заболеваниях
ES2701093T3 (es) Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
NZ586421A (en) IL-13 Binding agents
CA2749151A1 (en) Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody
BRPI0720280A2 (pt) Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
CA3080137A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP1159003B1 (en) Anti-tnf alpha antibodies in therapy of steroid resistant asthma
US20050089517A1 (en) Treatment of respiratory diseases with anti-IL-2 receptor antibodies
US20230035183A1 (en) Antibodies for the treatment of chronic graft versus host disease
JP2022549218A (ja) 抗トリプターゼ抗体の投薬
CA3169661A1 (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
KR20220030952A (ko) 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
KR20230121110A (ko) 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물,및 방법
EP4647084A1 (en) Method for treating asthma by using tslp antibody
NZ794353A (en) Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
NZ619873B2 (en) Methods and compositions for treating asthma using anti-il-13 antibodies

Legal Events

Date Code Title Description
EEER Examination request